T
he past decade has brought on a fundamental change with regard to our perspective on facial aging. Gravitational descent was implicated in the past as the principal mechanism by which facial aging occurred. Therefore, lifting procedures (e.g., face lift, brow lift, midface lift) served as the primary methods with which to address this process. Today, volumetric deficiency has also come to be increasingly recognized as a major component of the aging process, which can be addressed through a variety of techniques. Facial fat grafting and alloplastic implants have served as the principal surgical modalities for correcting the volume loss associated with facial aging. 1, 2 Poly-L-lactic acid can be thought of as an approximate nonsurgical equivalent to facial fat grafting. Serving in a rejuvenative capacity, poly-L-lactic acid is injected into the subcutaneous plane to gradually cause volumetric expansion over time. Unlike other dermal "fillers" that are intended to correct discrete facial deficiencies (e.g., lines, folds, and attenuated lips), poly-Llactic acid is designed to provide volumetric ex-pansion of volume-deficient areas. Approved for human immunodeficiency virus-related lipoatrophy by the U.S. Food and Drug Administration, poly-L-lactic acid can act to reverse the stigmata of malar and submalar soft-tissue depression in these patients, the improvement of which can be sustained in some reports for upward of 2 years. 3 Poly-L-lactic acid has also been used extensively in an off-label capacity to correct non-human immunodeficiency virusrelated facial volume loss.
Originally developed and marketed in Europe as New-Fill, poly-L-lactic acid has been successfully recruited for aesthetic indications since 1999 in over 150,000 clinical cases and in over 30 countries to date. The experience in the United States has been more cursory and dates back to August of 2004, when the product was first approved by the U.S. Food and Drug Administration for human immunodeficiency virus-related facial atrophy and marketed as Sculptra (Dermik Laboratories, Bridgewater, N.J.). Despite this relatively short period, the U.S. experience has contributed to an improved understanding of the expanded clinical indications of the product and the potential complications that can arise. This article is intended to summarize the current use of poly-L-lactic acid in the United States and enumerate the pearls and pitfalls that have informed the clinical practices of the authors. We will focus on the techniques (i.e., reconstitution, injection, and postoperative care) that may reduce the occurrence of adverse events, such as subcutaneous papules, and management of complications associated with poly-L-lactic acid.
PRODUCT INFORMATION
Injectable poly-L-lactic acid is a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Injectable poly-L-lactic acid, marketed as Sculptra, is composed of crystalline, irregularly sized microparticles of poly-Llactic acid. Poly-L-lactic acid has been used for numerous years in dissolvable suture material and other medical devices, including absorbable sealants, flow restrictors, fixation systems, and fixation screws, and in tissue regeneration. 4, 5 Sculptra is packaged as a sterile, freeze-dried preparation in a clear glass vial and is stable for 72 hours after reconstitution. The freeze-dried product can be stored at room temperature for up to 2 years and does not require refrigeration. Sculptra also contains sodium carboxymethylcellulose as a suspending agent to maintain even distribution of poly-L-lactic acid particles after reconstitution and nonpyrogenic mannitol that enhances the lyophilization process. Poly-L-lactic acid polymers degrade through nonenzymatic hydrolysis to lactic acid monomers, which are in turn metabolized into carbon dioxide or incorporated into glucose.
The mechanism by which injectable poly-Llactic acid engenders volumetric facial expansion is related to a foreign body giant cell reaction that occurs several weeks to months later. In addition, collagen production that occurs as the product degrades produces the observed volume changes and aesthetic benefit.
CLINICAL STUDIES
Two major clinical studies have been conducted into injectable poly-L-lactic acid in Europe: the VEGA study and the Chelsea and Westminster study. The VEGA study was a prospective, openlabel, single-center evaluation that included 47 patients with human immunodeficiency virus-related facial lipoatrophy who were studied over a period of 2 years and who attended up to six injection sessions, with one vial per cheek per session. Injection sessions were undertaken every 2 weeks, with the majority of patients (86 percent) completing four to five injections. Ultrasound measurements of mean skin thickness demonstrated a statistically significant three-fold increase in skin thickness, with results that were sustained over the 2-year evaluation.
2 Treatment-related adverse events that occurred included subcutaneous papules that arose on average 7 months (range, 0.3 to 25 months) after treatment initiation, with spontaneous resolution in 24 percent during the study.
The Chelsea and Westminister study was a 24-week, open-label, single-center, randomized evaluation that compared immediate versus delayed treatment in patients with human immunodeficiency virus-related facial lipoatrophy. All patients underwent three treatment sessions with one vial of poly-L-lactic acid per cheek. One arm of the study received treatment at 0, 2, and 4 weeks; the other arm, at 12, 14, and 16 weeks. In the immediate treatment group, significant changes in skin thickness were observed at week 12 when compared with the delayed treatment group, which had not been treated at that point. These changes were sustained for the duration of the 24-week study. In the delayed group, significant changes were not observed until week 24 and were equal to those of the immediate treatment group at that point. Data regarding Plastic and Reconstructive Surgery • September 1 Supplement, 2006 the occurrence of subcutaneous papules were not discussed in this study. 6 
MATERIALS AND METHODS

Technique
To date, the only U.S. Food and Drug Administration-approved indication in the United States for injectable poly-L-lactic acid is treatment of human immunodeficiency virus-related lipoatrophy. This article discusses treatment protocols that can be used for human immunodeficiency virusand non-human immunodeficiency virus-related facial volume loss and other regions of the body that warrant similar volume enhancement. Subcutaneous papules is the main complication that can arise after treatment with poly-L-lactic acid. Consequently, the techniques presented in this section have been developed to limit the incidence of subcutaneous papules and also obtain satisfactory results. These recommendations are derived from the clinical experiences of the authors and may differ from the guidelines presented in the literature that accompanies the manufactured product. These recommendations are not meant to be absolute or definitive but are culled from personal experience and should be followed with that caution and advisement in mind.
Reconstitution
Proper reconstitution of the freeze-dried product is a critical step in the avoidance of potential subcutaneous nodules. In the past, with the original studies presented, the product was reconstituted with 2 cc of sterile water. The authors have increasingly recognized the need for a much more copious amount of dilution to minimize the risk of nodule formation, with anywhere from 5 to 10 cc of sterile water per vial. As recommended, the sterile water is added the night before injection to permit sufficient time for the product to be entirely reconstituted. Although more abbreviated times have been used for reconstitution, the authors strongly recommend a minimum of 12 hours for reconstitution. An evenly distributed poly-Llactic acid hydrogel should diminish the incidence of clumping of the particulate poly-L-lactic acid. If the product is reconstituted only shortly before the time of injection, the risk of nodule formation may be accentuated.
Immediately before injection, additional local anesthetic (e.g., 1% lidocaine with 1:100,000 epinephrine) is recommended to be added to the vial to provide additional anesthesia and hemostasis.
Placement of 1 to 2 cc of local anesthesia will typically suffice to meet those objectives. With epinephrine in the mix, it is preferred that the lidocaine be added only shortly before the time of injection to ensure that its efficacy is not compromised. At this point, immediately before drawing up syringes for injection, the physician or assistant can swirl the vial more thoroughly to ensure an even suspension and reconstitution.
Injection
For patient comfort, it is advisable to apply a topical anesthetic with occlusive dressing over all of the treatment areas intended for enhancement. A dental block may improve patient comfort but has been found to be of little added benefit, given the wider arc of treatment that lies outside of the territory covered by a regional nerve block. The lidocaine with epinephrine that is recommended during the process of reconstitution can further optimize anesthesia.
With the patient in an upright position, the topical anesthesia is removed with a moist 4 ϫ 4 gauze and the patient more carefully inspected for areas that would benefit from volumetric enhancement. A wide-nibbed permanent marker is the preferred method of marking the patient in an upright position. The physician should avoid injecting directly through a skin mark to avoid the risk of a permanent traumatic tattoo.
At this point, the physician should calculate how best to distribute the poly-L-lactic acid across the areas of the face. Analyzing the face during the initial consultation is the most important aspect of obtaining the ideal results with poly-L-lactic acid. We typically use one vial per face, whereas previous studies from Europe have relied on two vials per face. If one vial of poly-L-lactic acid is to be used for the entire face and the vial is reconstituted with a total of 8.5 cc of diluent (e.g., a mixture of 6.5 cc of sterile water and 2 cc of lidocaine), the calculation can be based on this dilution (Fig.  1) . It is best to eliminate 0.5 cc from the calculation, as there is almost always some degree of spillage or waste in the syringe hub. With any extra amount left behind, the physician can easily distribute the remainder evenly between the two sides. The contrary is also true: if the physician was planning to place 4 cc on one side and 4 cc on the other side and ends up with only 3 cc on the remaining side, he is left with the potential for an asymmetric allocation. Thus, 1-cc Luer-Lok syringes are preferred for injection control and maintenance of accurate counts during injection.
Volume 118, Number 3S • Injectable Poly-L-Lactic Acid One-inch, 25-gauge Terumo (Somerset, N.J.) needles have been found to provide ease of injection and limited clogging. As the particulate nature of the suspension may occasionally lead to clogging in the needle, the physician should always withdraw the needle from the injection site to clear any obstruction before continuing.
Generally speaking, no more than two vials of reconstituted poly-L-lactic acid are recommended during any single treatment session to minimize the risk of overdelivery of product until additional experience is acquired. For the more mature patient or severely volume-depleted patient, even two to three vials of poly-L-lactic acid can be used during a single treatment session. However, using these high quantities in one treatment session risks nodularity, which can arise from placement of an excessive amount of product in a limited space (e.g., the perioral region). For the acolyte, starting with a single bottle for a single treatment session is recommended. As a good rule, the edema and volumetric fullness that accompany an 8-cc dilution of a single vial of poly-L-lactic acid is roughly equivalent to the way a patient will ultimately appear several months following a total of three vials. This estimation can prove to be effective in communicating with a patient about the number of treatment sessions that will be needed to achieve the desired aesthetic endpoint. For example, if the patient feels that he or she appears overcorrected, only one to two treatment sessions may be necessary. In contrast, if the patient believes that the volume gained immediately after injection still appears deficient, more than three treatment sessions may be required.
When calculating the areas for augmentation, it is advisable to divide each treatment area in half so that half of the treated area receives injection in one direction and the remaining half in the perpendicular cross-hatched fashion. Perpendicular cross-hatching facilitates a more even distribution ultimately than a unidirectional pass can afford. The depth of injection is one of the most important modifications in the authors' technique since the earlier recommendations. In the past, intradermal injection was advocated, but doing so may have led to a higher incidence of nodularity. The authors have found that the subcutaneous plane is the desired plane of distribution to minimize risk of this complication. No more than 
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0.1 cc of reconstituted poly-L-lactic acid per pass of the syringe should be injected, to minimize deposition of excess product into a discrete locus that might translate into nodule formation. Also, before each injection, the syringe should be gently flashed back to ensure that intravascular penetration has not been committed.
The malar and submalar regions are the easiest to correct and can show the greatest improvement, with minimal morbidity, using the aforementioned tunneling/cross-hatching method. Effacement of lines and folds is also possible with injectable poly-L-lactic acid (Fig. 2) but should be carried out with greater caution for two reasons. Volume 118, Number 3S • Injectable Poly-L-Lactic Acid
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First, placement of too much volume in a discrete area to manage a line or fold can lead to the potential for overcorrection and nodularity. Second, if the patient is truly desirous only of line effacement or modulation, the physician should opt for a true dermal filler that can provide a targeted solution to the problem with instantaneous results. The reader is reminded that with injectable poly-L-lactic acid, there is no visual endpoint: the physician simply places more product in an area with the prospect that over the ensuing weeks to months that area will manifest greater volume expansion.
The areas that should be avoided in the face for modification with poly-L-lactic acid are the lips and nose. Lip enhancement with poly-L-lactic acid is unpredictable. Although an estimate can be made with clinical experience of how much collagen growth will occur after a single treatment session, no certainty of a result can be firmly established. Accordingly, nasal augmentation is fraught with risk because the difference between an improvement and a deformity is within a millimeter or two of tolerance. It has also been observed that placement of poly-L-lactic acid into the neck can also lead to undesirable side effects of frequent nodularity and should be avoided.
The periorbital and temporal areas are also sensitive, albeit treatable, areas. Unlike the remainder of the face, these two zones should be addressed with conservative amounts in a depot rather than tunneling fashion. Periorbital enhancement should be reserved for more experienced surgeons who are familiar with treatment outcomes. We generally like to use an 11-cc dilution for this area. Generally speaking, to ameliorate the appearance of a hollow inferior orbital rim contour, two to three deep (supraperiosteal) depot (direct transcutaneous) injections are made across each bony rim with approximately 0.1 cc of aliquot per depot site evenly distributed across the rim. The injection sites are then immediately digitally massaged against the bone to enhance an even distribution. The area should be undercorrected, unlike the other regions of the face.
To manage temporal hollowing, the medial extent of the temporal hollow (i.e., the transition zone between a hollow temple and a fuller central forehead) is obscured with several depot deposits of 0.1 cc per site using approximately two to three evenly distributed injections, again deeply placed and massaged immediately thereafter. To reiterate, the temporal fossa is not augmented; rather, the transition zone between the temporal fossa and the medial forehead in the region of the conjoined tendon is muted. With these conservative recommendations, the physician can advance to more liberal guidelines with experience.
Other limited areas of the body can be addressed with Sculptra. These areas have included the hands and neck; décolleté and atrophic scars; and congenital, traumatic, and postsurgical depressions. The volumes and number of treatments necessary to correct the deficits vary, depending on individualized evaluation and response to treatment (Fig. 3) .
RESULTS
Posttreatment Care and Management of Expectations
Posttreatment care is centered on vigorous massage for several days to a week to distribute the product evenly and to limit the potential for untoward nodule formation. Immediately after treatment, massage should be undertaken using a moisturizer to facilitate ease of manipulation, which should be carried out in a deep, circular motion for approximately 5 minutes. A simple rule of thumb that the patient can easily recall for self-administered massage at home is the "3-3-3 rule" (i.e., 3 minutes of deep, circular massage with lubricant in the treated areas three times per day for 3 days).
The patient must understand clearly that the apparent volume at the end of the treatment session represents only edema and administered sterile water, all of which will dissipate in several days' time. The delayed effect of volumetric enhancement will not be observed for several weeks to even months after treatment. As an easy guide, patients can be counseled that after a single treatment, the perceived benefit is minimal and may not even be perceptible to the majority of patients. The rule proposed earlier should be recalled that the visual endpoint observed immediately at the conclusion of the treatment session approximates the aesthetic appearance after a total of three treatment sessions. Careful and standardized photographic documentation is indispensable for patient dialogue and maintenance of patient rapport. The patient must be counseled about the delayed pleasure of witnessing the aesthetic transformation, in contrast to the instant gratification that is attained with other types of fillers. In the past, the interval between sessions was only approximately 2 weeks. There is no definitive guideline as to the time between sessions, but we recommend it to be at least 4 to 6 weeks, to minimize the occurrence of nodularity and to evaluate the volumetric and tex-
tural changes from the injection. With additional treatment sessions, the physician should attempt to distribute the poly-L-lactic acid into a slightly deeper plane below the immediate subcutaneous plane where the first treatment session was conducted. Volume expansion can be seen several months after the initial injections; therefore, the interval between the third and subsequent sessions should be extended beyond the 6-week period, again to evaluate the necessity of further treatment.
Complications
The technical details outlined above are intended to direct the reader away from potentially harmful injection techniques and to navigate a safe course of therapy. Nevertheless, complications can and will most likely arise because of either technical error or an exposure to an increased number of patients over time. This section aims to classify the types of nodules that can arise and thereby outline a treatment strategy based on that classification scheme.
The major distinction of a palpable and/or visible lump after injectable poly-L-lactic acid is divided between a nodule and a granuloma. A nodule can be visible or nonvisible and may arise as a result of technical error, uneven distribution of the poly-L-lactic acid in the suspension, or uneven dispersal in the injected areas. It is distinguished by its indurated nature and separation from the surrounding soft tissue. It tends to remain the same size until it is absorbed, treated, or removed. Vleggaar, in this supplement, notes a nonvisible nodule rate of 3.2 percent and a visible nodule rate 1.2 percent, which resolved spontaneously in 26.9 percent and 7.7 percent, respectively. 7 Histologically, the nodule consists of fluid droplets or microparticles surrounded by a normal foreign body reaction. They typically arise only several weeks after injection. Conversely, granulomas may become apparent after many months to years, and they arise throughout the bed of implantation rather than at a few discrete loci. Their reported incidence ranges from 0.2 8 to 12 percent. 9 Using Volume 118, Number 3S • Injectable Poly-L-Lactic Acid a higher dilution of 5 cc for reconstitution rather than the earlier reconstitution volume of 3 cc, Vleggaar's six granulomas in 3000 patients (0.2 percent) is probably the most accurate. Unlike nodules, the borders of a granuloma are seldom well defined. Without treatment, they may grow over time, persist, and at times spontaneously resolve. They are characterized by erythema, edema, and a violaceous hue because of the abundance of congested capillaries. Although the cause remains unknown, at times a stimulus (e.g., systemic infection, trauma, operation) may trigger the immune memory of macrophages to induce a foreign body reaction. Treatment of nodules and granulomas is dissimilar and requires in-depth review. Nodules can be further subclassified into early and late nodules. Early nodules that appear within several weeks of treatment represent clustering of poly-L-lactic acid. The coalescence of these microparticles can be disrupted by means of several techniques: needle fragmentation of the nodule and injection of the nodule with saline to hydrate and redistribute the particles followed by aggressive massage. A LuerLok syringe with 1 to 3 cc of sterile water and a 25-gauge needle is the preferred method. These techniques may need to be repeated on a weekly basis until improvement or full resolution. If these lesions do not resolve over time, they can be locally excised. Late nodules that appear several months after injection may be treated with an intralesional steroid (triamcinolone, 10 mg/ cc) and massage. Again, failure to respond to these treatments may mandate local excision of the offending lesion. Since August of 2004, the authors have performed 325 injections on 144 patients. In only one patient has there been a postinjection nodule present (0.7 percent). No granulomas in this group have been seen thus far.
Granulomas are distinct entities that require a divergent treatment protocol. Local excision fails to address these entities which, when they arise, do so more pervasively and lack distinct borders, which makes excision untenable. Furthermore, surgical excision of a granuloma may lead to fistulas, abscesses, and scars. Steroid therapy (i.e., intralesional, intramuscular, and oral) with or without immune-modulating medications is the mainstay of intervention. Aggressive intralesional steroids with triamcinolone acetonide, 40 mg/cc, can be used every 3 weeks until resolution and may require one to 10 injections over 3 to 6 months for management.
Oral and intramuscular steroid therapy can be further supportive, as necessary. Also, 5-flurouracil (50 mg/cc) alone or in combination with Kenalog (1 mg/cc) or betamethasone (7 mg/ cc) can be beneficial and decrease the rate of steroid-induced skin atrophy.
10,11 Although we have not as yet had to treat any granulomas in our series, effective combinations have included a mixture of one-third 5-flurouracil (1.6 ml), one-third betamethasone (3.5 mg), and onethird lidocaine. 12 Vleggaar also reports successful treatment of granulomas with an intralesional injection of 0.4 cc of 5-flurouracil with 0.6 cc of Kenalog (10 mg/ml) weekly for up to 4 weeks and oral steroids and doxycycline (100 mg) for at least 8 weeks. 7 Intense pulsed light can play an adjunctive role in the treatment of engorged capillaries. At times, granulomas may resolve spontaneously. When treated and resolved, they rarely recur.
DISCUSSION
As with any aesthetic product, recommendations and guidelines are in a state of perpetual evolution and refinement. This article is intended to reflect current thinking regarding the techniques that can lead to potentially safer injection of poly-L-lactic acid. As stated, these recommendations are not meant in any way to be absolute but instead reflect personal experience.
In recent years, there has been a virtual plethora of new fillers and injectable agents developed for aesthetic purposes. Injectable poly-L-lactic acid remains in a distinct category, as aesthetic results are delayed and the principal objective is to restore volume and not to treat specific lines and folds per se. Unlike other dermal fillers, treatment is not undertaken until a visual endpoint is achieved. Instead, the product is distributed in the volume-deficient areas to await an empiric change over time.
As injectable poly-L-lactic acid is only specifically U.S. Food and Drug Administration-approved for human immunodeficiency virus-related lipodystrophy, published reports regarding its off-label indication have been sparse. 13 Furthermore, early manufacturer recommendations for poly-L-lactic acid use may have led to an unnecessary incidence of nodules. Specifically, intradermal injection, low-volume reconstitution, and aggressive use of the product may have contributed to a higher likelihood of untoward events. Although patient and injection numbers and length of follow-up are relatively low, it would appear that Plastic and Reconstructive Surgery • September 1 Supplement, 2006 a more conservative approach as described is thus far yielding a lower complication rate.
CONCLUSIONS
This article describes techniques for achieving safer results (i.e., subcutaneous injection, higher volume reconstitution, and a moderate timetable for therapy). In addition, a classification scheme has been proposed for types of complications that may arise and a treatment algorithm tailored accordingly. As ongoing clinical experience with injectable poly-L-lactic acid mounts in the United States, further refinements in on-label and offlabel usage will continue to surface. The authors hope that this article will help the novice and experienced practitioner with safe and effective implementation of injectable poly-L-lactic acid. 
